Kidney transplant drug showdown: which regimen saves more function?
NCT ID NCT01595984
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested two different combinations of immunosuppressant drugs in 88 adults who received a new kidney. The goal was to see which plan better protects kidney function over the short term. All participants took lifelong anti-rejection medication, so this is about managing the disease, not curing it.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for END-STAGE RENAL DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Nephrology Department, University Hospital of Montpellier
Montpellier, 34285, France
-
Nephrology department, Hospital University of Amiens
Amiens, 80000, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Which emergency dialysis saves more lives? a new study investigates
- Aging kidneys under the microscope: could a simple test predict failure?
- Can a new drug work safely in patients with kidney failure?
- Can dialysis change how a kidney drug works? a trial investigates
- What does life feel like for children with a rare birth defect? a new study asks
- AI therapy coach aims to ease distress in seriously ill seniors